Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with Advanced Tumours and Mismatch-Repair Deficiency
Envafolimab provided responses across various tumour types
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
The ELSA-seq Assay Provides Early Detection and Localisation Information in Multiple Cancers
The non-invasive ELSA-seq blood-based methylation sequencing assay demonstrated sensitivity and specificity
Futabatinib for Patients with Intrahepatic Cholangiocarcinoma and FGFR2 Fusions or Rearrangements
Intrahepatic cholangiocarcinoma has a higher incidence in Asian than in Western countries and carries a poor prognosis
Risk Factors for Recurrence Among Patients From Asia with Early Breast Cancer
Characteristics of patients from Asia enrolled in monarchE study
EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab)
Subcutaneous, fixed-dose combination of pertuzumab and trastuzumab is intended for the treatment of early and metastatic breast cancer
Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab Plus Ipilimumab as First-Line Treatment in Poor- and/or Intermediate-Risk Advanced RCC
Scientific assessment report following the application for a marketing authorisation published in “ESMO Open – Cancer Horizons”
Activity of Nivolumab and Ipilimumab Combination in the Treatment of Metastatic Uveal Melanoma
Results of phase II study with combination of two immune checkpoint inhibitors in rare subtype of melanoma
FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC
FDA also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic
FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers and Biomarkers
Indications concern identification of BRCA1 and/or BRCA2 mutations in ovarian cancer, PIK3CA mutations in breast cancer, ALK rearrangements in NSCLC, BRCA1, BRCA2, and/or ATM mutations in mCRPC
Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
Results of the first phase III study to evaluate the use of the UGT1A1 genotype for guiding the irinotecan dose in this setting
Identification of Actionable Molecular Alterations in NCI-MATCH
Feasibility of complex, genomically guided clinical trial in oncology
Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination Therapy in the S1320 Study
Intermittent treatment does not improve progression-free survival in BRAF-mutated melanoma